Antibody-Drug Conjugates in Non-small Cell Lung Cancer

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) are sophisticated therapeutics combining antibodies, linkers, and cytotoxic payloads.
• ADCs facilitate targeted delivery of chemotherapy to cancer cells via antigen binding and internalization.
• Their application in non-small cell lung cancer (NSCLC) is expanding, addressing treatment resistance.

Purpose of the Study:

• To review current data on ADC efficacy in non-small cell lung cancer (NSCLC).
• To emphasize the importance of patient selection, pharmacogenomics, and treatment sequencing for optimizing ADC therapy.
• To discuss the role of resistance mechanisms and predictive biomarkers in clinical practice.

Main Methods:

• Narrative review of existing clinical trial data for ADCs in NSCLC.
• Analysis of treatment strategies for both oncogene-addicted and non-oncogene-addicted NSCLC.
• Exploration of patient selection criteria, resistance mechanisms, and biomarker development.

Main Results:

• ADCs have demonstrated efficacy in phase II and III trials for previously treated advanced NSCLC.
• Ongoing trials are investigating ADCs in earlier disease stages and first-line settings.
• Improved patient selection is crucial for maximizing ADC benefits and minimizing toxicity.

Conclusions:

• ADCs represent a promising therapeutic option for non-small cell lung cancer (NSCLC).
• Further research into predictive biomarkers and resistance mechanisms is essential for refining ADC treatment strategies.
• Optimizing patient selection and treatment sequencing will enhance therapeutic outcomes in NSCLC.